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Summary. Cell death and cell cycle progression are two 
sides of the same coin, and these two different 
phenomenons are regulated moderately to maintain the 
cellular homeostasis. Tumor is one of the disease states 
produced as a result of the disintegrated regulation and is 
characterized as cells showing an irreversible 
progression of cell cycle and a resistance to cell death 
signaling. Severa1 investigations have been performed 
for the understanding of cell death or cell cycle, and cell 
death research has remarkably progressed in these 10 
years. Caspase is a nomenclature referring to ICEICED- 
3 cysteine proteinase family and plays a central role 
during cell death. Recently, severa1 investigations raised 
some possible hypotheses that caspase is also involved 
in cell cycle regulation. In this issue, therefore, we 
review the molecular basis of cell death and cell cycle 
regulated by caspase in tumor, especially hepatocellular 
carcinoma cells. 
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Fas IlgandIFas cell death-induclng system 
Fas is a type-1 transmembrane protein belonging to 
the nerve growth factorltumor necrosis factor receptor 
family (Itoh et al., 1991; Nagata, 1994). Tumor necrosis 
factor receptor-1 (TNF-R1 and ref. Old, 1985; Tartaglia 
et al., 1993) and TNF-related apoptosis-inducing ligand- 
receptor 112 (TRAIL-R1/2 and ref. Pan et al., 1997; 
Sheridan et al., 1997) also belong to the same family and 
these transmembrane proteins are closely involved in 
cell death induction. As shown in Fig. lA, this receptor 
family is characterized by a cysteine-rich extracellular 
NH2-terminal domain and one transmembrane domain. 
The four death-associated receptors, Fas, TNF-R1 and 
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TRAIL-R112, contain a unique domain in the 
cytoplasmic region which is necessary for the cell death 
signaling, which is referred to as the "death domain". It 
is known that lprllpr and lprcg/lprcg mutant mice are 
animal models for auto-immune disease (Watanabe- 
Fukunaga et al., 1992), and the functional lack of Fas in 
these mutant mice, which was caused by ETn insertion 
and a point mutation in the death domain, has been 
documented (Watanabe-Fukunaga et al., 1992). In 
addition, an inhibitory domain was identified in the 
cytoplasmic COOH-terminal region of Fas (Itoh and 
Nagata, 1993). Fas was originally identified during the 
search for an agonistic antibody against human TNF-R1 
(Yonehara et al., 1989). Fas has an essential role in cell 
death during clonal deletion of T cells, male and female 
reproductive tissue regression, estrous cycle, DES 
syndrome and tumor regression (Mapara et al., 1993; 
Nagata, 1994; Nagata and Golstein, 1995; Ogasawara et 
al., 1995; Suzuki et al., 1996a-c, 1997a). 
Fas transduces cell death signaling upon stimulation 
by its cognate ligand, known as the Fas ligand (Suda et 
al., 1993; Nagata, 1994; Nagata and Golstein, 1995). 
The Fas ligand is also a transmembrane protein (type-11) 
belonging to the tumor necrosis factor family (Fig. 1B 
and ref. Suda et al., 1993; Nagata, 1994; Nagata and 
Golstein, 1995). It has been reported that the gldlgld 
mutant model mouse for autoimmune disease involves 
the functional loss of Fas ligand (Nagata, 1994; 
Takahashi et al., 1994; Nagata and Golstein, 1995). In 
recent years, a close involvement of the Fas ligandpas 
death induction system has been suggested in liver 
failure, such as fulminant and viral hepatitis (Ogasawara 
et al., 1993; Hiramatsu et al., 1994; Kondo et al., 1997; 
Rodriguez et al., 1996a,b). Thus, Fas-mediated cell death 
has broad implications in a variety of clinical 
investigations. 
Caspase is the essential mediator for cell death 
signallng 
Among the known genes associated with cell death, 
caspase is the most important factor, since it plays the 
central role in cell death signaling. Caspase is the 
Switching mechanisms of tumor cell death and cell sun/ival 
nomenclature for the interleukin-lB converting enzyme 
(ICE)/CED-3 gene family and belongs to the cysteine 
proteinase family Alnemri et al., 1996). The CED-3 
death gene was identified originally from C. elegans, and 
ICE was detected as the human homologue 
demonstrating high similarity to CED-3 (Yuan et al., 
1993). Since overexpression of CED-3 or ICE induced 
cell death in mammalian cells (Miura et al., 1993), both 
the ICE and CED-3 genes were characterized as the cell 
death-associated gene. Since then, ten genes comprise 
the caspase family, and these are classified into three 
subfamilies, the caspase 1 (ICE)-, caspase 2 (ICH-1)- 
and caspase 3 (CPP32)-subfamilies (Fig. 2). Caspase 
activation has been well documented after various 
stimulations, such as the Fas ligand/Fas system (Enari et 
al., 1995, 1996; Tewari and Dixit, 1995), T N F - a m F -  
R1 system (Miura et al., 1995; Tewari and Dixit, 1995), 
chemical hypoxia (Jacobson and Raff, 1995; Shimizu et 
al., 1995, 1996a-c), chemotherapeutic agents (Suzuki 
and Kato, 1996; Suzuki et al., 1997b, 1998a,b) and 
amyloid B protein (Suzuki, 1997). The sequential 
activation of the caspase 1- and caspase 3-subfamilies is 
known as the "ICE cascade" (Enari et al., 1996). 
Within the caspase family members, the caspase 3 
subfamily, including caspase 3 (CPP32Nama/Apopain 
and ref. Fernandes-Alnemri et al., 1994; Nicholson et al., 
1995; Tewari et al., 1995) and caspase 8 (FLICEMCH 
and ref. Boldin et al., 1996; Muzio et al., 1996), plays 
the central role for cell death induction (Hasegawa et al., 
1996). Caspase 3 is the prototype factor for the caspase 
3-subfamily, and its essential role in physiological cell 
death and disease states during neurona1 development 
(Kuida et al., 1996) and liver failure (Rodriguez et al., 
1996a,b; Suzuki, 1998) has been well documented. Upon 
the stimulation of cell death, active caspase 3 processes 
PARP (Lazebnic et al., 1994), lamin (Lazebnik et al., 
1995), gelsolin (Kothakota et al., 199'7), ICAD (Enari et 
al., 1998) and Acinus (Sahara et al., 1999) to lead cells 
to die. 
Caspase and cell death slgnaling transduced by Fas 
As described above, Fas transduces cell death 
signaling upon stimulation by Fas ligand (Nagata, 1997). 
The intracellular cell death signaling is mediated by 
caspase activation at severa1 steps (Fig. 3), and the 
caspase-mediated death signaling is initially transduced 
by Fas-DISC (Fas-death-inducing signaling complex and 
ref. Kischkel et al., 1995) formation. Upon the 
stimulation of Fas, FADD and caspase 8 interacts with 
Fas-death domain, and the caspase 8 activated as a result 
of Fas-DISC formation proteolyses cytoplasmic serine 
proteinase-cleaved caspase 3 at p17 site (Suzuki et al., 
1997c; Thornbery et al., 1997). In addition, it has been 
known that caspase 3 activation during Fas-mediated 
cell death is initiated by mitochondrial death pathway; 
caspase 9 activated by ATP, Apaf-1 and apoptogenic 
cytochrome c (Liu et al., 1996; Zou et al., 1997), induce 
caspase 3 activation (Green and Reed, 1998) and this 
mitochondrial death pathway is initially triggered by 
caspase 8-cleaved Bid (Wang et al., 1996) after Fas- 
DISC formation (Li et al., 1998). Thus, caspase 3 which 
Flg. 1. Schematic model for NGFrrNF receptor family (A) and TNF family (B). Closed box (A) is the exiracellular cysteine-rich domain and shaded box 
(A) is the cytoplasmic "death domain". Shaded box in B is the high homology region within TNF family members. 
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was activated as a result of Fas-DISC recruitment andlor 
by mitochondrial death pathway, proteolyses severa1 
proteins. 
IAP family: Caspase 3 lnactlvator 
Caspase 3 activation has been well documented in 
Fas-mediated cell death, and its expression is observed 
endogenously in cells (Hasegawa et al., 1996). Caspase 
3 is the most influential cell death factor and its 
activation by a variety of stimuli means "instantaneous 
death". Why do cells hold such a dangerous factor? To 
address our question, we sought to identify an 
endogenous suppressor of cell death, assuming that ceils 
have a pathway that confers resistance against caspase 
activation. 
Bcl-2 is a known cell death suppressor and was 
identified originally as a proto-oncoprotein through the 
study of the t(14;18) translocation present in human B 
cell follicular lymphomas (Tsujimoto et al., 1984). Bcl-2 
localizes to the membrane of organelles and can be 
encountered on the nuclear membrane, endoplasmic 
reticulum and mitochondrial membrane (Akao et al., 
1994). Bcl-2 is unique in that it inhibits apoptosis rather 
than promoting cell proliferation (Tsujimoto, 1989; Vaux 
et al., 1988). Recently, multiple members have been 
identified within the Bcl-2 family, some functioning, 
such as Bcl-xs, Bax and Bak (Oltvai et al., 1993; 
Chittenden et al., 1996), to drive the death mechanism 
and others, such as Bcl-2 and Bcl-xL (Boise et al., 1993; 
Tsujimoto, 1989; Vaux et al., 1988), acting against 
apoptotic cell death. Bcl-2 expression suppressed Fas- 
mediated cell death (Itoh et al., 1993). Recently, the 
mitochondrial channel VDAC was identified as the 
target molecule of Bcl-2 and Bcl-xL (Shimizu et al., 
1999). By the interaction of Bcl-2 or Bcl-xL with 
VDAC, caspase 3 activation is prevented as a result of 
suppression of cytochrome c release from mitochondria 
(Shimizu et al., 1999). Thus, Bcl-2 and Bcl-xL indirectly 
suppress caspase 3 activation. In contrast, IAP family 
7 GCE-LAPJrnCh3aa) 
Caspase 3 (CPP32) subfamlly 
Fig. 2. The classification of caspase family members. 
proteins are direct inactivators of caspase 3 (LaCasse et 
al., 1998). The ability to suppress cell death by vira1 
gene products, such as crmA (cowpox virus and ref. Ray 
et al., 1992; Gagliardini et al., 1994; Miura et al., 1995; 
Tewari and Dixit, 1995; Tewari et al., 1995) and p35 
(baculo virus and ref. Clem and Miller, 1994; Xue and 
Horvitz, 1995), has been reported and the proteins 
suppress caspase activation by direct interaction. In 
recent years, ILP on the X chromosome, also called 
XIAP, has been identified as a member of the 
mammalian IAP family (Duckett et al., 1996; Deveraux 
et al., 1997). 
Human hepatoblastoma HepG2 cells do not express 
Bcl-2 (Suzuki et al., 1999~).  However, the cells show 
resistance to Fas-mediated cell death in the absence of 
actinomycin D (Suzuki et al., 1998a). Fas-mediated cell 
death in HepG2 cells was also mediated by caspase 3 
activation (Suzuki et al., 1998a). Interestingly, the 
proteolytic activity of human recombinant active caspase 
3 was suppressed by the addition of cell extracts from 
normal untreated HepG2 celis, and we identified ILP as 
the direct suppressor of caspase 3 activated during Fas- 
mediated cell death in HepG2 cells (Suzuki et al., 
1998a). However, we also demonstrated that ILP 
interacted only with active caspase 3, but not with 
procaspase 3, and co-immunoprecipitation analysis 
identified p21, the cell cycle suppressor (Nakanishi et 
al., 1995; Sherr and Roberts, 1995), as the interactive 
Fig. 3. i iw schematic model loi F a e - W u c e d  cell death stgnaling. 
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protein with procaspase 3. 
Caspase 3 inactivation by p21 and ILP 
As described above, we identified severa1 caspase 3 
inactivators, including p21 (for procaspase 3) and ILP 
(for active caspase 3). As shown in Fig. 4, the binding 
domain for p21 or ILP was detected in the NH2- 
tenninus @21) or in the active region (ILP) of caspase 3 
(Suzuki et al., 1999a). Interestingly, the p21-binding 
domain of caspase 3 overlapped the p3 cleavage site for 
a serine proteinase (Suzuki et al., 1997c, 1999a). When 
p21 suppressed caspase 3 activation during Fas-mediated 
cell death, we demonstrated proteolytic activity of a p3 
cleavage serine proteinase, suggesting that p21 
suppresses caspase 3 activation by blocking the p3 
cleavage site as a result of the interaction. On the other 
hand, the ILP-binding domain was found in the active 
region of caspase 3. Since IAP family members, 
including crmA, p35 and ILP, can directly suppress 
caspase activation (Clem and Miller, 1994; Gagliardini 
et al., 1994; Miura et al., 1995; Suzuki et al., 1998a, 
1999a; Tewari and Dixit, 1995; Tewari et al., 1995; Xue 
and Horvitz, 1995), it appears that the detection of an 
ILP-binding domain in the active region is reasonable. 
Many proteinase inhibitors, including proteins and 
chemical compounds, have a direct interaction with the 
active region of their target proteinase. ILP may be a 
better inhibitor of caspase 3. As a first step for caspase 3 
inactivation, p21 interacts with procaspase 3 to shield the 
p3 site cleavage, and ILP suppresses caspase 3 activation 
in the case of emergency. Thus, cells are protected from 
"sudden death" or "accidental death" by this two-step 
caspase 3 inactivation (Suuki et al., 1998a, 1999a). 
Protein phosphorylation and procaspase 31~21  
complex formation 
p21 was originally reported as a cell cycle 
suppressor (Harper et al., 1993), and p21 suppresses the 
kinase activity of cyclin-dependent kinase and regulates 
p53 to arrest the cell cycle at G1 (Li et al., 1994; Sherr 
and Roberts, 1995). The role of p21 in cell death 
induction has been reported, and we suggest that this 
p21-associated cell death induction is due to p53 whose 
expression is  induced by p21, since p53 induces 
apoptotic cell death via the Fas 1igandIFas system 
(Hueber et al., 1997; Bennett et al., 1998). In contrast, 
cell death suppression by p21 was recently reported from 
our (Suzuki et al., 1998a, 1994a,b, 2000c) and other 
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Flg. 4. Caspase 3 inactivation by p21 and ILP. The functional domains in p21 and caspase 3 are drawn schematically. The typical suppression of Fas- 
mediated cell death by GST-p21 and GST-ILP was obse~ed with Hoechst 33342lPl staining. 
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(Hobeika et al., 1999; Xu and El-Deiry, 2000) 
laboratories. Furthermore, a recent study demonstrates 
an interesting role for p21 in cell cycle progression, in 
that cell cycle arrest by p53 is regulated by Arf which is 
the alternative reading frame product of tumor 
suppressor INK4a (Hirai et al., 1995; Quelle et al., 
1995), but not by p21 (Weber et al., 1999). Moreover, 
p21 is involved in cell cycle initiation by acting as a 
stabilizer of cyclin and cyclin-dependent kinase (Cheng 
et al., 1999; Sherr and Roberts, 1999). Thus, the role of 
p21 in cell death and cell cycle remains unclear. 
In our studies, when cells overexpressed p21, Fas- 
mediated cell death was completely suppressed and co- 
immunoprecipitation analysis revealed an endogenous 
interaction of procaspase 3 and p21 (Suzuki et al., 
1998a). We identified the binding domain for the 
procaspase 3 1 ~ 2 1  complex formation in the NH2- 
terminal amino acid sequences (Suzuki et al., 1999a). 
According to the procaspase 31~21 complex formation, 
p21 masked the p3 cleavage site of procaspase 3 and 
protected procaspase 3 from serine proteinase-induced 
activation (Suzuki et al., 1999a). On the basis of these 
results, we questioned what factor(s) initiated the 
procaspase 3 1 ~ 2 1  complex formation. Immuno- 
fluorescence analysis revealed p21 subcellular 
localization in both the nucleus and the cytoplasm 
(Suzuki et al., 1999b), consistent with p21 involvement 
in the cell cycle, ceil cycle arrest via p53 regulation (Li 
et al., 1994), or cell cycle initiation by the stabilization 
of cyclin and cyclin-dependent kinase (Cheng et al., 
1999). Furthermore, immunoblotting analysis of 
fractionated proteins revealed p21 in the mitochondrial 
fraction (Suzuki et al., 1999b). As described above, the 
mitochondrion is a recent focus in the cell death research 
field. Therefore, we prepared cells lacking 
mitochondrion and showed that mitochondria are 
necessary for the procaspase 3 1 ~ 2 1  complex-initiated 
resistance to Fas-mediated cell death (Suzuki et al., 
1999b). Human hepatoblastoma HepG2 cells show Fas- 
mediated cell death only in the presence of actinomycin 
D, whereas HepG2Am (mitochondrion-lacking HepG2) 
cells showed it even in the absence of actinomycin D 
(Suzuki et al., 1999b). In addition, while HepG2Am cells 
showed dissociation of the procaspase 31~21 complex, 
they did not show any changes in the expression levels 
of caspase 3 or p21 (Suzuki et al., 1999b). In other 
words, free procaspase 3 activated smoothly without a 
p21 influence upon stimulation of Fas in these cells. 
Moreover, we showed a deprivation of intracellular KIT 
in HepG2Am cells. During the Fas-mediated cell death, a 
drastic reduction of intracellular ATP was observed 
(Suzuki et al., 2 0 0 0 ~ ) .  In recent years, protein 
phosphorylation as a cell survival system has been 
investigated, and Akt and protein kinase A (PKA) are 
well documented as the cell survival-associated protein 
phosphatases. Akt is activated by PI-3 kinase as a result 
of phosphorylation at Thr308 and Ser473 (Ahmed et al., 
1997; Kennedy et al., 1997; Datta et al., 1999) and active 
Akt phosphorylates the Bcl-2 family cell death agonist 
Bad (Datta et al., 1997; Peso et al., 1997), Forkhead 
transcriptional factor (Brunet et al., 1999) and caspase 9 
(Cardone et al., 1998). In addition, it has been reported 
that active Akt suppresses Fas-DISC (death-inducing 
signaling complex and ref. Kischkel et al., 1995) 
formation (Rohn et al., 1998). PKA was also recently 
documented as a cell survival factor due to induction of 
Bad phosphorylation (Harada et al., 1999). 
We showed a reduction in intracellular AiT during 
Fas-mediated cell death and Fas-mediated cell death in 
the absence of actinomycin D by intracellular ATP 
deprivation (Suzuki et al., 2 0 0 0 ~ ) .  Using specific 
inhibitors for protein phosphatases, we demonstrated 
that PKA, but not Akt, was involved with the resistance 
to Fas-mediated cell death and procaspase 3 1 ~ 2 1  
complex formation was initiated as a result of p21 
phosphorylation by PKA (Suzuki et al., 2000~). Upon 
the phosphorylation of p21 by PKA, the phosphorylated 
p21 translocates and interacts with procaspase 3 on the 
outer mitochondrial membrane. Thus, procaspase 3 is 
inactivated by an interaction with p21 under the 
influence of PKA and intracellular ATP, and the resultant 
procaspase 31~21 complex initiates celi survival in cells 
(Fig. 5). 
Procaspase 31~21 complex formation as a result of 
cell cycle progression by survivln 
Notable characteristics of tumor cells include high 
growth rates and cell survival stemming from resistance 
CELL SURVIVAL 
Fig. 5. The schernatic rnodel for procaspase 31~21 cornplex forrnation. 
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to ceil death signaling. Suwivin is a recently identified 
IAP family protein (Ambrosini et al., 1997), and its 
expression is detected specifically in tumor celis (Adida 
et al., 1998a; Kawasaki et al., 1998; Lu et al., 1998; 
Swana et al., 1999) and in cells during embryonic 
development (Adida et al., 1998b). Compared with other 
IAP family members, such as crmA, p35, iap and ILP 
(Clem and Miller, 1994; Gagliardini et al., 1994; Miura 
et al., 1995; Xue and Howitz, 1995; Duckett et al., 1996; 
Deveraux et al., 1997), survivin contains a single 
baculovirus IAP repeat, lacks a carboxyl-terminal RING 
finger and is unique in that its expression is observed 
only in proliferating cells, including tumor cells. Thus, 
possible involvement of survivin in cellular proliferation 
is suggested (Ambrosini et al., 1998). However, the 
molecular details are not understood. 
Caspases 3 and 7 have been identified as the target 
molecule binding proteins in a celi-free system (Tamm et 
al., 1998). When cells expressing high levels of 
exogenous survivin were stimulated with Fas, the ability 
to suppress cell death with suwivin was weaker than 
with ILP (Suzuki et al., 2000a). We also observed 
survivin-interactions with caspase 3 in a cell-free 
system. However, co-immnuprecipitation analysis 
revealed that endogenous survivin interacted with 
cyclin-dependent kinase (Cdk) 4, but not with caspase 
(Suzuki et al., 2000a). In addition, we demonstrated 
nuclear translocation of suwivin following up-regulation 
of cell growth (Ito et al., 2000; Suzuki et al., 2000a,b). In 
cells overexpressing survivin, retinoblastoma (Rb) 
protein phosphorylation was observed as well as 
upregulation of CdWcyclin E complex kinase activity (S 
phase progression marker). Moreover, we also 
demonstrated that p21 was released from the Cdk4fcyclin 
D1 complex and translocated to the mitochondrial outer 
membrane, and that procaspase 31~21 complex formation 
on mitochondria was accelerated (Ito et al., 2000; Suzuki 
et al., 2000a,b). Thus, our results suggested that survivin- 
initiated cell death suppression was due to accelerated 
procaspase 31~21 complex formation, rather than a direct 
interaction with caspase. 
There is some evidence that survivin is involved in 
cell cycle progression. First, suwivin translocates into 
the nucleus following upregulation of cell growth 
activity. Second, survivin overexpression and nuclear 
translocation induces Rb phosphorylation, up-regulation 
of Cdk2fcyclin E complex kinase activity and the S 
phase population. Finally, suwivin interacts directly with 
Cdk4. When survivinICdk4 complex formation was 
suppressed by a functional loss of survivin, Rb 
phosphorylation, and up-regulation of Cdk2fcyclin E 
complex kinase activity and the S phase population was 
prevented (Suzuki et al., 2000b), suggesting that 
survivinfCdk4 complex formation is an important 
element for cell cycle progression. It has been reported 
that INK4a directly interacts with Cdk4 and leads to G1 
Flg. 6. The correlation of cell death, cell cycle and cell survival. 
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arrest (Hirai et al., 1995; Byeon et al., 1998; Parry et al., 
1999; Stein et al., 1999). Interestingly, we also 
demonstrated that INK4a overexpression leads to G1 
arrest, but survivin prevented this as a result of a 
competitive interaction of survivin with the Cdk4/INK4a 
complex (Suzuki et al., 2000b). Survivin appears to 
displace INK4a from its complex with Cdk4. 
Resistance to Fas-mediated cell death by HGF: Akt 
activation and Fas-DISC recruitment 
The resistance to Fas-mediated cell death has been 
well documented when cells were treated with some 
growth factors, such as basis FGF (fibroblast growth 
factor and ref. Kazama and Yonehara, 2000). In recent 
years, cell survival signaling transduced by hepatocyte 
growth factor (HGF) has also been well investigated. 
HGF initiates cell survival signaling in severa1 cells, 
such as ovarian cell, renal cell and neurona1 cell (Liu, 
1999; Ueoka et al., 2000; Zhang et al., 2000). This cell 
survival signaling is mediated by Akt/PI-3 kinase 
pathway after c-Met interaction and we have 
demonstrated that human HCC (hepatocellular 
carcinoma cell) lines showed the cell survival mediated 
by HGF-activated Akt (Suzuki et al., 2000d). 
It is known that HGF activates Akt/PI-3 kinase 
andlor Ras/MAP kinase pathway (Jones et al., 1999; 
Ueoka et al., 2000; Zhang et al.,, 2000). HGF suppressed 
HCC cell death transduced by Fas activation and the cell 
death signaling was reacquired by Akt inhibition, but not 
by MAP kinase inhibition (Suzuki et al., 2000d). 
Furthermore, we demonstrated that activated Akt by 
HGF suppressed Fas-DISC recruitment (Suzuki et al., 
2000d). As described above, it has been documented that 
active Akt inactivated Bad and caspase 9, and 
suppressed Fas-DISC recruitment (Datta et al., 1997; 
Peso et al., 1997; Cardone et al., 1998; Rohn et al., 
1998). HCC lines do not express Bad (Suzuki et al., 
1999c) and the death signaling by Fas is not mediated by 
caspase 9-involved mitochondrial death pathway 
(Suzuki et al., 1999b, 2000a). Ras1MA.P kinase pathway 
also suppresses Fas-mediated cell death (Kazama and 
Yonehara, 2000) and HGF activates RasIMAP kinase 
pathway (Jones et al., 1999). However, our results 
showed no involvement of RasIMAP kinase pathway in 
the resistance to Fas-mediated cell death by HGF in 
HCC lines, at least. 
Cell death, cell survival and cell cycle in HCC 
Until recently, most studies of cell death, cell cycle 
and cell survival have progressed independently. There 
is now greater interaction between the research fields 
and, importantly, a greater appreciation that research of 
cell death, cell cycle andlor cell survival are two sides of 
the same coin. 
Through the results of our work and those of others, 
molecular machinery and essential regulators for cell 
death, cell cycle and cell survival have been elucidated 
(Fig. 6). Both ceil cycle progression and cell survival are 
essential for tumor cells, including HCC. Caspase 3, 
whose activation is initiated as a result of Fas-DISC 
recruitment, is the most essential killer factor and plays 
the central role during Fas-mediated cell death. Caspase 
3 activation is suppressed by p21: Procaspase 3/p21 
complex formation on mitochondria is under the 
influence of PKA and intracellular ATP and this 
complex formation is initiated as a result of p21 release 
from its complex form with Cdk4 by survivin. The 
survividCdk4 complex up-regulates Rb phosphorylation 
through Cdk2lcyclin E complex activation and leads 
cells to S phase entry. Thus, p21 released during the 
survivin-induced cell cycle progression suppresses cell 
death and the cells acquire resistance to cell death and 
cell cycle progression. 
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